Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma
复制标题
晚期肺鳞状细胞癌卡铂和纳米颗粒白蛋白结合紫杉醇诱导治疗后改用 S-1 维持治疗
DOI：
10.1007/s10637-019-00747-x
复制
发表时间：
2019
影响因子：
3.4
通讯作者：
Fujii
中科院分区：
文献类型：
--
作者：
Akiyama Norimichi;Karayama Masato;Inui Naoki;Yasui Hideki;Hozumi Hironao;Suzuki Yuzo;Furuhashi Kazuki;Fujisawa Tomoyuki;Enomoto Noriyuki;Nakamura Yutaro;Inami Nao;Matsuura Shun;Kaida Yusuke;Uto Tomohiro;Matsui Takashi;Asada Kazuhiro;Matsuda Hiroyuki;Fujii
背景：肺鳞状细胞癌（SCC）的最佳维持治疗尚未确定。本研究的目的是评估在卡铂和纳米颗粒白蛋白结合紫杉醇（nab-paclitaxel）诱导治疗chemotherapy-naïve晚期SCC患者后，口服氟嘧啶S-1切换维持治疗的疗效和安全性。MethodsChemotherapy-naïve晚期SCC患者接受4个周期的卡铂诱导治疗（在6曲线下的区域，28天周期的第1天）和nab-紫杉醇（100 mg/kg，第1、8和15天）。诱导治疗后达到疾病控制的患者接受S-1维持治疗（80 mg/m2, 21天周期的第1-14天），直到疾病进展或不可接受的毒性。主要终点是从维持治疗开始的无进展生存期（PFS）。结果72例SCC患者入组研究。诱导治疗4个周期后，35例（48.6%）患者获得疾病控制，其中31例（43.1%）患者接受维持治疗。从维持治疗开始的中位PFS为3.0个月（95%置信区间：2.1-3.8个月）。在维持治疗期间，最常见的3级或更高的毒性是恶心（13.3%）、中性粒细胞减少（10.0%）和腹泻（6.7%）。结论在卡铂和nab-紫杉醇诱导治疗后切换S-1维持治疗具有中等疗效和可接受的安全性，可能是晚期SCC患者的可行治疗选择。
BackgroundOptimal maintenance therapy for lung squamous cell carcinoma (SCC) has not been established. The aim of this study was to evaluate the efficacy and safety of switch maintenance therapy with S-1, an oral fluoropyrimidine, after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in chemotherapy-naïve patients with advanced SCC.MethodsChemotherapy-naïve patients with advanced SCC received induction therapy with four cycles of carboplatin (at an area under the curve of 6, day 1 of a 28-day cycle) andnab-paclitaxel (100 mg/kg, days 1, 8, and 15). Patients who achieved disease control after induction therapy received maintenance therapy with S-1 (80 mg/m2, days 1–14 of a 21-day cycle) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) from the start of maintenance therapy.ResultsSeventy-two patients with SCC were enrolled to the study. After four cycles of induction therapy, 35 (48.6%) patients achieved disease control, and 31 (43.1%) of these patients received maintenance therapy. Median PFS from the start of maintenance therapy was 3.0 months (95% confidence interval: 2.1–3.8 months). The most common toxicities of grade 3 or higher during maintenance therapy were nausea (13.3%), neutropenia (10.0%), and diarrhea (6.7%).ConclusionsSwitch maintenance therapy with S-1 after induction therapy with carboplatin andnab-paclitaxel was associated with moderate efficacy and acceptable safety and may represent a feasible treatment option for patients with advanced SCC.
登录
查看更多内容
影响因子：
158.5
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
通讯作者：
Johnson, David H.
晚期非鳞状非小细胞肺癌初治患者接受卡铂和培美曲塞诱导治疗后培美曲塞与多西他赛维持治疗的比较：一项随机 II 期研究
影响因子：
3
作者：
M. Karayama;N. Inui;Shigeki Kuroishi;K. Yokomura;M. Toyoshima;T. Shirai;M. Masuda;Takashi Yamada;Kazumasa Yasuda;T. Suda;K. Chida
通讯作者：
K. Chida
影响因子：
50.5
作者：
Planchard, D.;Popat, S.;Peters, S.
通讯作者：
Peters, S.
影响因子：
5.3
作者：
Niho, Seiji;Ohe, Yuichiro;Goto, Koichi
通讯作者：
Goto, Koichi
影响因子：
5.3
作者：
Janssen-Heijnen, MLG;Schipper, RM;Coebergh, JWW
通讯作者：
Coebergh, JWW